Peripheral Artery Disease
Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
Published in Blood Weekly, March 20th, 2008
Vermillion, Inc. (NASDAQ:VRML), a high-value molecular diagnostics company, announced that it has entered into an exclusive license agreement with Stanford University to develop and commercialize a novel biomarker panel used to assess the risk of peripheral artery disease (PAD). Estimated to affect up to 12 million Americans, PAD is a serious condition that often goes undiagnosed. The disease can result in severe complications, including gangrene, amputation, heart attack, stroke and even death.
Under the terms of the agreement, Vermillion is granted exclusive rights to the biomarker panel, and will undertake the development and commercialization of a PAD blood test,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2008-03-20)
More Articles from Blood Weekly
- Ebola Hemorrhagic Fever
Penn scientists find a protein that inhibits Ebola from reaching out to infect neighboring cells - Macromolecular Science
Researchers engineer new polymers to change their stiffness and strength when exposed to liquids - Acute Lymphoblastic Leukemia
Researchers at Karolinska University release new data on acute lymphoblastic leukemia - Acute Osteomyelitis
Research from Sultan Qaboos University, Medical Department has provided new information about acute osteomyelitis - Acute Promyelocytic Leukemia
Study data from George Washington University provide new insights into acute promyelocytic leukemia - Alpha-thalassemia
Studies from J.D. Lafferty and co-researchers update current data on alpha-thalassemia - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
